Loading
The seeds stay in the prostate and give off most of their radiation in the first few months, almost all of it absorbed inside you. You can be around other people normally. For about two months, avoid having children on your lap for long and avoid long close contact with anyone pregnant, use a condom for the first few ejaculations in case a seed comes out, and carry the card you are given.
Release follows the same framework as other radioactive treatments: before discharge the physicist or radiation protection officer confirms that doses to others will stay within public limits and carer constraints, with assumptions matching the written instructions (IAEA SSG-46 5.258; in the US no other person likely to exceed 5 mSv, 10 CFR 35.75). ICRP 98 found that in the vast majority of cases the dose to carers stays well below 1 mSv a year, and that only a partner who is pregnant at the time of implantation may need specific precautions. Measured dose rates from 1,279 patients (Dauer 2010) found no precautions needed for a typical palladium-103 patient, and for a typical iodine-125 patient only avoiding sleeping in contact with a pregnant partner and long periods holding a child on the lap, for about two months; Prostate Cancer UK gives the same two months, with 50 cm from children beyond a few minutes a day and from pregnant women beyond three hours.
Written instructions also cover a seed coming out (rare; most likely in the first month) and what to do (SSG-46 5.260; ICRP 98); UK patients are told to use a condom for the first five ejaculations and not to pick up a seed passed in urine but to flush it away. A wallet card carries the implant details for later pelvic or abdominal surgery, for radiation security monitors and in case of death (SSG-46 5.261; ICRP 98). Cremation is the one point where sources differ widely: ICRP 98 allows it once 12 months have passed after iodine-125 (3 months after palladium-103), while Prostate Cancer UK says cremation is not possible in the first 20 months and to carry the card for at least 20 months. ICRP 98 notes that fathering a child remains possible after an implant.
Why: The precautions given only need to be as strict as the measured activity requires.
“In the case of carers and comforters, the assumptions made for the calculations should be consistent with the written instructions that will be given at the time the patient is discharged from the facility.”
International Atomic Energy Agency, jointly sponsored by PAHO and WHO 2018
Why: Children and unborn babies are the most sensitive to radiation; for adults the dose is very small.
“Individuals of particular concern are children and pregnant partners of patients.”
International Atomic Energy Agency, jointly sponsored by PAHO and WHO 2018
Why: Measured doses to the people around a patient with seeds are well below the yearly public limit.
“The available data show that, in the vast majority of cases, the dose to comforters and carers remains well below the recommended limit of 1 mSv/year. Only the (rare) case where the patient's partner is pregnant at the time of implantation may need specific precautions.”
International Commission on Radiological Protection (Annals of the ICRP 35(3)) 2005
Why: Palladium-103 decays faster and gives a lower dose rate; for iodine-125 only long, very close contact matters.
“For the typical Pd-103 patient, no radiation-safety precautions are required.”
Dauer et al., Brachytherapy (NIH author manuscript PMC3819139) 2010
Why: Seeds occasionally come out in urine or semen, most often in the first month; a single seed is low in activity but should be handled properly.
“There is a low probability of an implanted seed being expelled, for example with prostate treatment. The written instructions should cover this possibility and should provide guidance on what to do and what not to do.”
International Atomic Energy Agency, jointly sponsored by PAHO and WHO 2018
Why: A surgeon needs to know about the seeds, and the card explains a radiation detector alarm at an airport.
“The patient with permanent brachytherapy implants should be informed that, if he or she is to undergo subsequent surgery, the surgeon should be informed of the presence of the implants; for example, a prostate cancer patient undergoing subsequent pelvic or abdominal surgery.”
International Atomic Energy Agency, jointly sponsored by PAHO and WHO 2018
Why: Ashes may hold radioactivity if cremation happens soon after the implant, so it may need to wait.
“Review of available data shows that cremation can be allowed if 12 months have elapsed since implantation with I-125 (3 months for Pd-103).”
International Commission on Radiological Protection (Annals of the ICRP 35(3)) 2005
Why: Men who do not want a child need to know contraception still matters.
“However, although the therapy-related modifications of the semen reduce fertility, patients must be aware of the possibility of fathering children after such a permanent implantation, with a limited risk of genetic effects for the child.”
International Commission on Radiological Protection (Annals of the ICRP 35(3)) 2005
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
Release after a physicist's check that doses to others stay within public limits and carer constraints, with written instructions focused on children and a pregnant partner, advice on a seed being expelled, and a wallet card for later surgery, security monitors and death (IAEA SSG-46 2018; ICRP 98 2005; 10 CFR 35.75). Measured dose rates support short, light precautions: none for a typical palladium-103 patient and about two months of avoiding long close contact with children and pregnant women for iodine-125 (Dauer 2010; Prostate Cancer UK 2026). The sources disagree on cremation: ICRP 98 allows it 12 months after iodine-125 and 3 months after palladium-103; UK patient information says not within 20 months. None of the sources grades its advice.
International Atomic Energy Agency, jointly sponsored by PAHO and WHO 2018 · International Commission on Radiological Protection (Annals of the ICRP 35(3)) 2005 · Dauer et al., Brachytherapy (NIH author manuscript PMC3819139) 2010 · US Nuclear Regulatory Commission (Code of Federal Regulations, via eCFR) 2007 · Prostate Cancer UK 2026
Where it differs: For the first two months: no closer than 50 cm to children for more than a few minutes a day (a quick cuddle is fine, not on the lap), not this close to pregnant women for more than three hours, and no pets on the lap. Avoid sex for a few days, use a condom for the first five ejaculations and double-wrap used condoms in the bin. A seed passed in urine at home is flushed away, not picked up. No cremation within 20 months; carry the card for at least 20 months.
Evidence: Patient information reviewed by a consultant clinical scientist; it gives no evidence grades. The 20-month cremation interval is longer than the ICRP's 12 months for iodine-125, and the page does not say why.
Where it differs: The dose rate at 30 cm from the skin is measured after the implant and put into an equation that gives the precaution time for each situation (pregnant partner, children on the lap), keeping doses to others below half the public limits. Most patients then need far shorter precautions than a fixed rule; a rare iodine-125 patient at the highest measured rate would need much longer ones.
Evidence: Measurements from 1,279 patients at one US centre; the authors found the resulting precaution times significantly less restrictive than those generally prescribed, which they report as 1 to 3 months for palladium-103 and 2 to 6 months for iodine-125.
Dauer et al., Brachytherapy (NIH author manuscript PMC3819139) 2010
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Release with written instructions; children and pregnant partners of particular concern “As indicated in para. 5.258, the patient or the legal guardian of the patient should be provided with written instructions on how to keep doses to members of the public and carers and comforters as low as reasonably achievable.” | Safety Guide recommendation (ungraded) | International Atomic Energy Agency, jointly sponsored by PAHO and WHO 2018 |
| Systematic dose monitoring of family members is not necessary after permanent prostate implants “Published data suggest that systematic dose monitoring, at least in the case of permanent brachytherapy implanted sources for the treatment of prostate cancer, is not necessary” | Safety Guide recommendation (ungraded) | International Atomic Energy Agency, jointly sponsored by PAHO and WHO 2018 |
| A wallet card with the implant details “A 'wallet card' with all relevant information about the implant is useful.” | Consensus (ungraded) | International Commission on Radiological Protection (Annals of the ICRP 35(3)) 2005 |
| Release where no other individual is likely to exceed 5 mSv (US), which covers implants as well as unsealed sources “A licensee may authorize the release from its control of any individual who has been administered unsealed byproduct material or implants containing byproduct material if the total effective dose equivalent to any other individual from exposure to the released individual is not likely to exceed 5 mSv (0.5 rem).” | Regulatory requirement (ungraded) | US Nuclear Regulatory Commission (Code of Federal Regulations, via eCFR) 2007 |
Shares Low-dose-rate seed brachytherapy, Brachytherapy (internal radiotherapy), Brachytherapy, Prostate cancer.
Shares Brachytherapy (internal radiotherapy), Brachytherapy, Prostate cancer.
Shares Low-dose-rate seed brachytherapy, Brachytherapy (internal radiotherapy), Brachytherapy, Prostate cancer.
Shares Brachytherapy (internal radiotherapy), Brachytherapy.
Shares Bladder filling and rectal preparation for prostate radiotherapy, Prostate cancer.
Shares Bladder filling and rectal preparation for prostate radiotherapy, Prostate cancer.
Shares Prostate cancer.
Shares Prostate Cancer UK, Prostate cancer.